It is reported that the insulin was specially collected in June last year165438+1October and produced successful results. In the first year of centralized procurement, the procurement demand was 2 1 100 million pieces, involving an amount of10.70 billion pieces. The average price of selected commodities dropped by 48%, with the highest drop of 73%. It is estimated that after centralized procurement, the annual cost of insulin will be saved by about 9 billion yuan, which will further reduce the drug burden for more than100000 patients who need long-term or even lifelong insulin injection.
The price of the product selected in the centralized procurement of insulin is the payment standard, and the medical insurance fund pays according to the prescribed proportion. Non-selected insulin products belong to the scope of medical insurance fund payment, and the payment standard does not exceed the highest selected price of the same category of products or the negotiated price of medical insurance. Patients use non-selected products, and the part whose price exceeds the medical insurance payment standard is paid by the patients themselves. All localities should make overall consideration of online price setting, patient payment ratio and medical insurance payment standard, and strive to reduce the burden of patients' expenses.
Insulin is a commonly used drug to treat diabetes. Since May this year, the varieties selected in the national centralized procurement of insulin drugs have been implemented in various places, with an average price reduction of 48%.
Wu Jianjun, a diabetic in Hunan, comes to the endocrinology department of Hunan Provincial People's Hospital every month to inject long-acting insulin. Since May 3rd, Kloc-0, Wu Jianjun has experienced obvious price changes.
Patient Wu Jianjun: In the past, each 190 was more than RMB, about three a month. Now they only want 79 yuan.
It not only lightens the burden of patients, but also improves the continuity of patients' medication, which is very beneficial to control the development of the disease. At present, there are 654.38+0.4 billion diabetic patients in China, and more than 654.38+0.0 billion patients need long-term or even lifelong insulin injection. This time, 32,000 medical institutions participated in the insulin demand report. In the first year, the procurement demand was 2 1 10,000 pieces, involving an amount of10.70 billion pieces. It is estimated that after the collection, the annual cost of insulin can be saved by about 9 billion yuan.
Want to know more financial news in real time, please pay attention to us.